Impact Factor
3.37
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.43
146 total citations
h5-index
14
h5 depth signal
Cited share
91.4%
32 of 35
Total citations
146
Citation footprint
Metric signal
2.48
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
145
Italy
55
China
54
France
41
United Kingdom
38
Citing Fields of Research
HIV
185
Hepatitis
165
Virology
66
Viral Identification & Phylogenetics
31
Immunology
15
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,513
Articles tracked across the journal lifetime
Indexed publication set
35
32 cited publications
Last 12 months
12
1.5 publications/month
Open access share
100.0%
12 OA publications in the last year
Leading citing country
United States
145 citing publications
Leading citing field
HIV
185 citing publications
Latest tracked publication
28 September 2026
10 recent records available
Coverage & Indexing History
v1n1,1996-
v1n1,1996-
Active Coverage
Research Focus & Classification
Indexed Subjects
HIV
Virology
Hepatitis
Viral Identification & Phylogenetics
Issuing & Sponsoring Bodies
Contributor
International Society for Antiviral Research
Broad Categories
Anti-Infective Agents
Virology
HIV
Hepatitis
MeSH Descriptors
Antiviral Agents
Virus Diseases
Viruses
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/13596535261490958
Open DOI
Kidney function parameters in South African children living with HIV on antiretroviral therapy
Background: We evaluated longitudinal kidney function in children with perinatally acquired HIV (CWH) compared with HIV-negative controls. Methods: We analyzed data from an observational study in Johannesburg, South Africa (2013–2018), i...
02
DOI 10.1177/13596535261479944
Open DOI
COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial
Background: COMBO 1 compared time to cessation of viral shedding (TCVS) among hospitalized influenza patients treated with oseltamivir plus a single dose of baloxavir vs. oseltamivir alone. Methods: In a quadruple-blinded, placebo-contro...
03
DOI 10.1177/13596535261481194
Open DOI
Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study
Background: ARTISTRY-1 is an ongoing Phase 2/3 study evaluating the safety and efficacy of once-daily oral bictegravir (BIC) + lenacapavir (LEN) in virologically suppressed (VS; HIV-1 RNA <50 copies/mL) participants on complex antiretrov...
04
DOI 10.1177/13596535261436877
Open DOI
Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series
Objective: The objective was to evaluate the safety, pharmacokinetics and efficacy of an alternative deltoid site for CAR-LA. Design: This is a prospective cohort of people living with HIV (PLWHIV) switching for intramuscular long acting...
05
DOI 10.1177/13596535261450699
Open DOI
Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review
Objective: This systematic review summarizes factors associated with immunological non-response (INR) among people with HIV on antiretroviral therapy (ART) in Southeast Asia. Methods: We conducted a systematic search of PubMed, ScienceDi...
06
DOI 10.1177/13596535261440692
Open DOI
Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey
Background: Posttransplant cytomegalovirus (PT-CMV) infection remains a challenging complication and a major cause of morbidity and mortality in transplant recipients. Methods: This cross-sectional study surveyed physicians treating soli...
07
DOI 10.1177/13596535261438178
Open DOI
It’s about time: The association between abacavir and cardiovascular disease
Data from the REPRIEVE trial have been used to study the association between treatment with abacavir and cardiovascular disease in people with HIV. Past exposure to abacavir before the trial was found to be just as risky as exposure duri...
08
DOI 10.1177/13596535261444510
Open DOI
Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study
Background: Intravenous hyper-immune anti-cytomegalovirus immunoglobulins (CMV-IG) therapy are licensed for prophylaxis, yet their therapeutic value in established CMV disease remains poorly defined. We aimed to evaluate the clinical and...
09
DOI 10.1177/13596535251405027
Open DOI
Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage In silico study
Ebola virus is a member of the Filoviridae family, which causes hemorrhagic fever in primates, exhibiting a mortality rate that can reach up to 90%. The VP35 suppresses the host IFN- β/α production by disrupting the immune responses of t...
10
DOI 10.1177/13596535251405300
Open DOI
Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection
Severe influenza infections involve an exacerbation of the pro-inflammatory response, which is influenced by both viral and host factors. Protectins PD1 and PDX previously demonstrated anti-influenza activity as well as anti-inflammatory...
Bibliographical & Catalog Notes
Description based on: Vol. 3, no. 4 (1998); title from cover.
Supplements accompany some v.
Also issued online.
Official publication of the International Society for Antiviral Research.